Indomethacin

Indomethacin is a nonsteroidal anti-inflammatory drug belonging to the acetic acid derivative subclass, specifically an indole acetic acid compound with the molecular formula C19H16ClNO4 ^[1]. Like other NSAIDs it combines analgesic, anti-inflammatory, and fever-reducing actions, but it is notably potent, which underlies both its usefulness and its comparatively high rate of side effects ^[1]. The name indometacin is the international nonproprietary name, while indomethacin is the name adopted in the United States; it has been sold under trade names such as Indocin and Indocid ^[1].

The drug emerged in the early 1960s from a broad search for effective anti-inflammatory and analgesic agents, the same effort that produced other acetic acid derivatives such as diclofenac and sulindac ^[1]. It was patented in 1961 and introduced for medical use in 1963, when it was described as a new non-steroid anti-inflammatory agent effective in rheumatoid arthritis, gout, osteoarthritis, and ankylosing spondylitis ^[2]. Indomethacin was among the most potent of the early NSAIDs and one of the first to be used for migraine and related headaches ^[1].

Its principal uses are in inflammatory and painful joint conditions, including acute gout, ankylosing spondylitis, rheumatoid and osteoarthritis, and bursitis or tendinitis, where its strength makes it a common choice for severe flares ^[2]. A distinctive feature is its role in a family of primary headache disorders, the so-called indomethacin-responsive headaches such as paroxysmal hemicrania and hemicrania continua, which respond dramatically and often completely to indomethacin but not to other NSAIDs ^[4]. In neonatal medicine, intravenous indomethacin is used to close a patent ductus arteriosus in preterm infants, although comparative studies indicate that ibuprofen and acetaminophen are also effective for this purpose ^[5]. It is sometimes used to delay premature labor as well ^[1].

Indomethacin is a prescription medicine available as capsules, a sustained-release form, suppositories, an intravenous preparation, and topical products, and it is included on the World Health Organization list of essential medicines ^[1]. Because it strongly inhibits the protective prostaglandins of the gut and kidney, it carries a substantial risk of stomach irritation, ulcers, gastrointestinal bleeding, fluid retention, raised blood pressure, and impaired kidney function, and it can cause headache and dizziness ^[1]. It is generally used at the lowest effective amount for the shortest time, is often paired with a stomach-protecting drug, and is avoided in late pregnancy and in people with active ulcers, significant kidney disease, or certain other conditions ^[1].

Indomethacin is prescription strength and is one of the harder NSAIDs on the body, so it is used at the lowest effective dose for the shortest time. Like all NSAIDs it can cause stomach upset, ulcers, and gastrointestinal bleeding, raise blood pressure, cause fluid retention, and reduce kidney function, and it carries a raised risk of heart attack and stroke. It causes more central nervous system effects than other NSAIDs, such as headache and dizziness. It should be avoided late in pregnancy, in active ulcers, and in significant kidney disease, and used cautiously in older adults. It interacts with blood thinners, other NSAIDs, lithium, and some blood-pressure drugs.

Indomethacin increases plasma lithium concentrations by decreasing renal lithium ion elimination by approximately 23 percent, causing steady-state lithium levels to rise by about 40 percent ^[8]. This is a pharmacokinetic interaction mediated through indomethacin's inhibition of renal prostaglandin synthesis, which reduces lithium clearance ^[8]. The clinical significance is high because the narrow therapeutic window of lithium means this increase can precipitate lithium toxicity ^[8].

Aspirin alone does not produce this effect on lithium clearance despite similar platelet inhibition, making it a preferable alternative in lithium-treated patients ^[8]. NSAIDs more broadly interact with warfarin through both pharmacodynamic and pharmacokinetic mechanisms, but the specific interaction of indomethacin with warfarin or other coumarins has not been systematically documented. Interactions with ACE inhibitors or other agents affecting renal hemodynamics have not been systematically studied with indomethacin specifically, though NSAIDs broadly impair the effectiveness of antihypertensives.

Checking a whole stack? Run it through interactions + stacks.

Indomethacin was developed by researchers at Merck and introduced in the 1960s as a potent nonsteroidal anti-inflammatory drug of the indole acetic acid class, one of the earlier synthetic agents created specifically to combat inflammation. Its mechanism was illuminated by the landmark work on prostaglandins for which Sir John Vane and colleagues later shared a Nobel Prize; classic experiments showed that indomethacin, like aspirin, abolished the release of prostaglandins from tissue, helping to establish cyclooxygenase inhibition as the shared basis of NSAID action.

Over subsequent decades it became a mainstay for acute gout, ankylosing spondylitis, and other inflammatory arthritis, earning a reputation as one of the stronger NSAIDs available. It also acquired distinctive specialized roles, including the closure of a patent ductus arteriosus in premature infants and the treatment of an unusual group of indomethacin-responsive headaches. Its enduring clinical importance is reflected in its inclusion on the World Health Organization list of essential medicines. It remains widely used where potent anti-inflammatory effect is required.

Indomethacin is respected as one of the more powerful nonsteroidal anti-inflammatory drugs, a longstanding go-to when strong relief of pain and inflammation is needed. Clinicians rely on it for acute gout and ankylosing spondylitis, and it holds a place on the World Health Organization list of essential medicines. What most distinguishes it, however, is a set of near-signature roles: it is uniquely effective in a group of indomethacin-responsive headache syndromes, including paroxysmal hemicrania and hemicrania continua, where its swift and often complete relief is so reliable that responsiveness itself helps define the diagnosis.

It also serves a specialized function in closing a patent ductus arteriosus in premature infants. In candid terms, its broad, nonselective blockade of prostaglandins brings a meaningful risk of gastrointestinal and kidney side effects, so it is used thoughtfully and often for limited periods. Where its particular strengths apply, it can be remarkably, sometimes dramatically, effective.